Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.55 |
| ▸ | GABBR2 | O75899 | 4/20 | 0.54 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3123820 | 0.86 | GABBR2 (0.64) | ABCG2GABBR2GABBR1MAPTLMNA | |
| SCHEMBL3112867 | 0.83 | GABBR2 (0.61) | GABBR2GABBR1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL3117412 | 0.80 | GABBR2 (0.70) | GABBR2GABBR1MAPTALDH1A1IRAK1 | |
| SCHEMBL3123747 | 0.78 | GABBR2 (0.75) | GABBR2GABBR1MAPTIRAK1IRAK4 | |
| SCHEMBL27735613 | 0.78 | GABBR2 (0.56) | GABBR2GABBR1IRAK1IRAK4 | |
| SCHEMBL3122586 | 0.77 | GABBR2 (0.67) | GABBR2GABBR1IRAK1IRAK4 | |
| SCHEMBL3118460 | 0.75 | GABBR2 (0.53) | GABBR2GABBR1IRAK1IRAK4 | |
| SCHEMBL3120412 | 0.75 | GABBR2 (0.77) | GABBR2GABBR1IRAK1IRAK4 | |
| SCHEMBL3116087 | 0.75 | GABBR2 (0.74) | GABBR2GABBR1LMNAIRAK1IRAK4 | |
| SCHEMBL13248616 | 0.74 | GABBR2 (0.65) | GABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | DPYD, NUDT1, HPRT1 | ABCG2 76/4885GABBR2 1611/4885GABBR1 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.